Skip to main content
Rhett Schiffman, MD, Ophthalmology, Irvine, CA

Rhett Mead Schiffman MD MS MHSA


Physician

Join to view full profile
  • 118 Med Surge # 1Irvine, CA 92697

  • Phone+1 949-824-6211

  • Fax+1 949-824-4015

Dr. Schiffman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Henry Ford Health/Henry Ford Hospital
    Henry Ford Health/Henry Ford HospitalResidency, Ophthalmology, 1993 - 1996
  • Henry Ford Health/Henry Ford Hospital
    Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1983 - 1986
  • Universidad Autonoma de Ciudad Juarez
    Universidad Autonoma de Ciudad JuarezClass of 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - 2027
  • MI State Medical License
    MI State Medical License 1984 - 2004
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Ophthalmology
    American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Phase 3 Presbyopia Drop Trial Launches
    Phase 3 Presbyopia Drop Trial LaunchesApril 6th, 2022
  • Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of Directors
    Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of DirectorsAugust 25th, 2021
  • Visus Therapeutics Expands Ophthalmic Drug Portfolio with Investigational Therapies for Glaucoma and Age-Related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology
    Visus Therapeutics Expands Ophthalmic Drug Portfolio with Investigational Therapies for Glaucoma and Age-Related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery TechnologyAugust 19th, 2021

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: